by Jonathan Goodman, MPhil
Hispanic and Non-Hispanic Black patients were significantly underrepresented, but Asian/Pacific Islander patients were overrepresented.
Clinical trials of PARP inhibitors in patients with ovarian cancer do not accurately reflect the racial and ethnic makeup of the real-world … Read more
by Anne Doerr
A new study led by researchers at Yale Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to … Read more
A drug currently used to treat skin and lung cancers has been found to slow the progression of a form of ovarian cancer and increase the number of patients who respond to treatment, a clinical trial has found.
As a … Read more
by Monica Janke, MD
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved
by Jon Kelvey
Black patients with ovarian cancer were less likely than their White counterparts to receive adjuvant chemotherapy after primary surgery, according to a study published in Gynecologic Oncology.
The study also showed that patients who did not undergo … Read more
by Ariana Pelosci
Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.
A combination regimen of paclitaxel
… Read moreby Kristi Rosa
The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.
The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced
by Brielle Benyon
Amma was developed by a cancer survivor who wanted an easier — and cheaper — way for patients to preserve their hair during chemotherapy treatment.
The Food and Drug Administration (FDA) granted clearance to Amma, a scalp-cooling
by Sucharita Mistry, PhD
Cytoreductive surgery followed by chemotherapy can prolong overall survival (OS), compared with chemotherapy alone, in certain patients with relapsed ovarian cancer, according to results from the DESKTOP III trial published in the New England Journal of … Read more
by Nichole Tucker
Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.
Single-agent mirvetuximab soravtansine (mirvetuximab; IMGN853) has demonstrated clinically meaningful benefit in patients with late receptor alpha (FRα)-high platinum-resistant
by Steve Tally
Purdue-developed imaging drug allowed surgeons to find additional cancer lesions
Left image: A drug used for fluorescent imaging during ovarian cancer surgeries, which was just approved by the FDA, lights up cancer cells “like stars against a … Read more
By Mike Bassett
— Programs frequently using this treatment achieved these declines without compromising OS
Cancer programs that were more likely to use neoadjuvant chemotherapy to treat advanced ovarian cancer saw larger declines in short-term mortality versus programs with less … Read more
A RAF/MEK plus FAK inhibitor combination will be given an expedited review by the FDA as therapy for patients with recurrent low-grade serous ovarian cancer.
By Audrey Sternberg
The combination of the RAF/MEK inhibitor, VS-6766, plus the FAK inhibitor, defactinib, … Read more
By Jennifer Southall
The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical Oncology… Read more
RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.
By … Read more
For patients with recurrent platinum-resistant epithelial ovarian cancer who were naïve to PD-1/PD-L1 inhibition, the combination treatment of tislelizumab plus sitravatinib showed early antitumor activity while maintaining a manageable safety profile.
By Kristi Rosa
For patients with recurrent platinum-resistant epithelial
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
The research from UVA’s Jogender Tushir-Singh, PhD, explains why … Read more
